Arrowhead Pharmaceuticals (ARWR) stock gains as company reassures investors about financial obligations required from Sarepta ...

Bank of America downgraded Sarepta Therapeutics (NASDAQ:SRPT) to Underperform from Neutral on Wednesday, becoming the latest brokerage to issue a bearish view on the company, citing safety concerns ...

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025.. "In the first quarter, we achieved net product ...

We note that Sarepta Therapeutics, Inc. (NASDAQ:SRPT) does have debt on its balance sheet. But the real question is whether this debt is making the company risky. When Is Debt Dangerous?

We expect Sarepta Therapeutics SRPT to beat expectations when it reports fourth-quarter and full-year 2023 results. In the last reported quarter, the company delivered an earnings surprise of 72.29%.

Shares of Sarepta Therapeutics SRPT have surged 76.8% in the past three months compared with the industry’s 10.2% rise. Sarepta’s commercial portfolio consists of three RNA-based PMO therapies ...

Sarepta Therapeutics Inc. (NASDAQ: SRPT) jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company’s experimental gene therapy to treat Duchenne ...

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS, the only approved gene therapy for patients with Duchenne ...

The stock price of Sarepta Therapeutics (NASDAQ:SRPT), a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) insiders who purchased shares in the last 12 months were richly rewarded last week. The stock climbed by 5.3% resulting in a US$375m addition to the ...

Sarepta recorded total revenues of $253.5 million, up 20.2% year over year. Revenues beat the Zacks Consensus Estimate and our model estimate of $223.2 million and $221.4 million, respectively.

CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the ...